| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2011;1(1):76-79.
Invited Perspective
Peptoid and positron emission tomography: an appealing combination
Weibo Cai, Hao Hong
Departments of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin,
USA; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
Received July 31, 2011; accepted August 2, 2011; Epub August 3, 2011; Published August 15, 2011
Abstract: Non-invasive and quantitative imaging of tumor angiogenesis is essential for lesion detection, patient stratification, drug
development, and personalized anti-cancer therapies. In particular, the right timing is critical for anti-angiogenic cancer therapy and
non-invasive imaging can help determine whether to start and when to start such treatment. In this inaugural issue of the American
Journal of Nuclear Medicine and Molecular Imaging, a peptoid-based positron emission tomography (PET) tracer was reported for
imaging of VEGFR expression in a prostate cancer model. This important proof-of-principle study opened the door to a fertile area of
research, which holds tremendous potential for various applications in future personalized medicine.
(ajnmmi1107003).
Keywords: Peptoid, cancer, tumor angiogenesis, positron emission tomography (PET), molecular imaging, 64Cu
Full text PDF
Address all correspondence to:
Weibo Cai, PhD
Departments of Radiology and Medical Physics
University of Wisconsin
Room 7137, 1111 Highland Ave
Madison, WI 53705-2275, USA.
Tel: 1-608-262-1749 ; Fax: 1-608-265-0614
Email: wcai@uwhealth.org
Invited Perspective
Peptoid and positron emission tomography: an appealing combination
Weibo Cai, Hao Hong
Departments of Radiology and Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin,
USA; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
Received July 31, 2011; accepted August 2, 2011; Epub August 3, 2011; Published August 15, 2011
Abstract: Non-invasive and quantitative imaging of tumor angiogenesis is essential for lesion detection, patient stratification, drug
development, and personalized anti-cancer therapies. In particular, the right timing is critical for anti-angiogenic cancer therapy and
non-invasive imaging can help determine whether to start and when to start such treatment. In this inaugural issue of the American
Journal of Nuclear Medicine and Molecular Imaging, a peptoid-based positron emission tomography (PET) tracer was reported for
imaging of VEGFR expression in a prostate cancer model. This important proof-of-principle study opened the door to a fertile area of
research, which holds tremendous potential for various applications in future personalized medicine.
(ajnmmi1107003).
Keywords: Peptoid, cancer, tumor angiogenesis, positron emission tomography (PET), molecular imaging, 64Cu
Full text PDF
Address all correspondence to:
Weibo Cai, PhD
Departments of Radiology and Medical Physics
University of Wisconsin
Room 7137, 1111 Highland Ave
Madison, WI 53705-2275, USA.
Tel: 1-608-262-1749 ; Fax: 1-608-265-0614
Email: wcai@uwhealth.org
 |  |  |  |  |  |  |